STOCK TITAN

Zai Lab Announces Upcoming Participation in September Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

SHANGHAI and SAN FRANCISCO, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced that Dr. Samantha Du, Founder, Chairwoman and Chief Executive Officer of Zai Lab, will be presenting at the following upcoming virtual conferences in September. Details of the virtual conferences are as follows:

Citi’s 15th Annual Biopharma Virtual Conference
Presentation: Thursday, September 10, 2020 at 8:55 a.m. ET

JP Morgan’s Women’s Leadership Conference
Presentation Event: Tuesday, September 29, 2020 | 10:30 a.m. – 2:30 p.m. ET

Webcast or external link of the company presentations will be available under “Events & Presentations” in the “Investors Relations” section of Zai Lab’s website. Archived replays will be available for approximately 90 days following the event.

About Zai Lab

Zai Lab (NASDAQ:ZLAB) is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world. To quickly target the large, fast-growing segments of China’s pharmaceutical market and address unmet medical needs, Zai Lab’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates. Zai Lab has also built an in-house team with strong drug discovery and translational research capabilities, aiming to establish a global pipeline of proprietary drug candidates against targets in our focus areas. Zai Lab’s vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its portfolio in order to impact human health worldwide.

For additional information about the company, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.

For more information, please contact:

ZAI LAB CONTACTS:

Zai Lab
Billy Cho, CFO
+86 137 6151 2501
billy.cho@zailaboratory.com

Media: Ryo Imai / Robert Flamm, Ph.D.
Burns McClellan, on behalf of Zai Lab
212-213-0006 ext. 315 / 364
rimai@burnsmc.com / rflamm@burnsmc.com

Investors: Pete Rahmer / Mike Zanoni
Endurance Advisors, on behalf of Zai Lab
415-515-9763 / 610-442-8570
prahmer@enduranceadvisors.com / mzanoni@enduranceadvisors.com

Zai Lab Limited


Zai Lab Limited American Depositary Shares

NASDAQ:ZLAB

ZLAB Rankings

ZLAB Latest News

ZLAB Stock Data

2.08B
887.81M
1.83%
44.84%
3.9%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SHANGHAI

About ZLAB

zai lab is a biopharmaceutical company dedicated to discovering, developing and commercializing innovative medicines. our vision is to address the largest unmet medical needs and transform patients’ lives around the world. we take a unique approach to combine both in-licensed products and internal r&d; to achieve a rich pipeline. we believe our drug candidates can be truly disease modifying and bring significant benefits to patients. the company was founded in 2013 by a group of industry veterans. the founders are known as pioneers in china’s fast advancing biotech industry with a proven track record for successful chinese cfda and us fda filings and approvals. our senior management team introduced fast regulatory approval pathways in china and developed a variety of partnership models with multinational pharmaceutical companies. we endeavor to conduct world class clinical development in china and beyond. zai lab has strong backing from a leading group of healthcare investors. our inve